ArticleCancer medicine2026
Analysis of Age, Period and Cohort Trends in Cervical In Situ and Invasive Carcinomas for Assessing the Utility of Screening Approaches-Results From the Saarland Cancer Registry.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer continues to pose a significant public health burden. In Germany, prevention relies heavily on regular screening and HPV vaccination.
objectiveTo analyze trends in cervical cancer incidence over a 50-year period in Saarland, Germany, with a focus on cohort effects and the impact of screening programs.
methodsData from the Saarland Cancer Registry were evaluated for the period 1970-2023. Trends in cervical carcinoma (ICD-10: C53, ICD-9: 180) and carcinoma in situ (ICD-10: D06, ICD-9: 233.1) were analyzed, stratified by age and birth cohort. Additionally, model-based age-period-cohort analyses were derived. The D06/C53 ratio was calculated by age group and calendar period.
resultsSince the introduction of Pap smear screening in 1971, the age-standardized incidence of cervical cancer declined by 74%. Subsequently, sharp decreases were observed in women born in 1933 or earlier. Women who grew into screening never reached the high pre-screening rates. Concurrently, in situ carcinoma incidence rose more than tenfold, with detection concentrated in women aged 30-39, indicating a shift toward earlier detection. The D06/C53 ratio increased across all age groups, most strongly in women ≤ 39 years. Overall mortality fell by 71%, although no significant further decline was observed over the last two to three decades.
conclusionThis analysis underscores the substantial impact of cervical cancer screening in reducing both incidence and mortality, particularly among women of screening age. The increasing D06/C53 ratios point to a shift toward earlier detection and treatment of lesions, although cancer registry-based data cannot fully distinguish prevented progression from overdiagnosis. While the effects and benefits of screening are already well established, the first effects of HPV vaccination are only beginning to emerge. To build on these achievements, sustained efforts to enhance both screening uptake and HPV vaccine coverage are imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.